Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Tourmaline Bio, Inc. Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights November 07, 2024 From Tourmaline Bio, Inc. Via GlobeNewswire Tickers TRML Tourmaline Bio to Present at Upcoming Investor Conferences October 31, 2024 From Tourmaline Bio, Inc. Via GlobeNewswire Tickers TRML Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November 1, 2024 October 15, 2024 From Tourmaline Bio, Inc. Via GlobeNewswire Tickers TRML Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress October 11, 2024 From Tourmaline Bio, Inc. Via GlobeNewswire Tickers TRML Tourmaline Bio Announces Formation of Cardiovascular Scientific Advisory Board October 08, 2024 From Tourmaline Bio, Inc. Via GlobeNewswire Tickers TRML Tourmaline Bio to Present at Upcoming Investor Conferences September 03, 2024 From Tourmaline Bio, Inc. Via GlobeNewswire Tickers TRML Tourmaline Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights August 08, 2024 From Tourmaline Bio, Inc. Via GlobeNewswire Tickers TRML Tourmaline Bio Presents Phase 2 TRANQUILITY Study Design at American Society of Preventive Cardiology (ASPC) Congress 2024 August 02, 2024 From Tourmaline Bio, Inc. Via GlobeNewswire Tickers TRML Tourmaline Bio Announces the Promotion of Ryan Robinson to Chief Financial Officer June 27, 2024 From Tourmaline Bio, Inc. Via GlobeNewswire Tickers TRML Tourmaline Bio to Present at the Jefferies Global Healthcare Conference May 23, 2024 From Tourmaline Bio, Inc. Via GlobeNewswire Tickers TRML Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial May 16, 2024 From Tourmaline Bio, Inc. Via GlobeNewswire Tickers TRML Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights May 13, 2024 From Tourmaline Bio, Inc. Via GlobeNewswire Tickers TRML Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights March 19, 2024 From Tourmaline Bio, Inc. Via GlobeNewswire Tickers TRML Tourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares January 29, 2024 From Tourmaline Bio, Inc. Via GlobeNewswire Tickers TRML Tourmaline Bio Announces Pricing of Public Offering of Common Stock January 25, 2024 From Tourmaline Bio, Inc. Via GlobeNewswire Tickers TRML Tourmaline Bio Announces Proposed Public Offering of Common Stock January 24, 2024 From Tourmaline Bio, Inc. Via GlobeNewswire Tickers TRML Tourmaline Bio Announces Expected Upcoming Key Milestones for the Clinical Development of TOUR006, a Long-Acting Subcutaneous Inhibitor of IL-6 with Best-in-Class Potential, in Thyroid Eye Disease (TED) and Atherosclerotic Cardiovascular Disease (ASCVD) January 08, 2024 From Tourmaline Bio, Inc. Via GlobeNewswire Tickers TRML Tourmaline Bio added to the NASDAQ Biotechnology Index December 15, 2023 From Tourmaline Bio, Inc. Via GlobeNewswire Tickers NBI TRML Tourmaline Bio Appoints Dr. Clay Siegall as Chairman of the Board December 14, 2023 From Tourmaline Bio, Inc. Via GlobeNewswire Tickers TRML Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million October 19, 2023 From Tourmaline Bio, Inc. Via GlobeNewswire Tourmaline Bio Appoints Gerhard Hagn as SVP, Head of Commercial and Business Development September 20, 2023 From Tourmaline Bio, Inc. Via GlobeNewswire Tourmaline Bio Announces FDA Clearance of Investigational New Drug (IND) Application for TOUR006, an anti-IL-6 antibody with a differentiated profile for the treatment of thyroid eye disease (TED) August 28, 2023 From Tourmaline Bio, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
